---
figid: PMC3376977__onci-1-38-g2
figtitle: NK cells sense tumors, course of disease and treatments
organisms:
- NA
pmcid: PMC3376977
filename: onci-1-38-g2.jpg
figlink: /pmc/articles/PMC3376977/figure/F2/
number: F2
caption: 'Figure 2. Tumors parameters implicated in the activation of NK cells. In
  RCC, VHL mutations induce constitutive activation and accumulation of Hypoxia-inducible
  factor (HIF). Certain VHL mutations correlate with low HLA-I molecules expression
  via a partially HIF-dependent pathway. The low expression of HLA-I molecules by
  VHL-mutated RCC cells reduces the engagement of NKG2A inhibitory receptor, shifting
  the balance toward NK cell activation. Membrane HLA-G molecules upregulate inhibitory
  receptors (NKG2A,and ILT2) on NK cells. Membrane-bound IL15 (Mb-IL15) is involved
  in NK cell activation and survival. In CML, the oncogeneic protein bcr/abl induces
  the expression of ICAM-1 and NKG2D ligands on myeloid cells favoring NK/target conjugates
  and lysis. Altered IFNγ signaling in bcr/abl target maintains a low HLA-I molecules
  expression. Bcr/abl dendritic cells activate NK cells via NKG2D receptor. Imatinib
  mesylate interferes with NK/leukemic targets. DC: Dendritic cell; IM: Imatinib Mesylate;
  IRF: Interferon regulatory factor; STAT-1: Signal Transducer and Activator of Transcription
  factor-1.'
papertitle: NK cells sense tumors, course of disease and treatments.
reftext: Giulia Fregni, et al. Oncoimmunology. 2012 Jan 1;1(1):38-47.
year: '2012'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.6793189
figid_alias: PMC3376977__F2
figtype: Figure
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
redirect_from: /figures/PMC3376977__F2
ndex: 23440d84-df33-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3376977__onci-1-38-g2.html
  '@type': Dataset
  description: 'Figure 2. Tumors parameters implicated in the activation of NK cells.
    In RCC, VHL mutations induce constitutive activation and accumulation of Hypoxia-inducible
    factor (HIF). Certain VHL mutations correlate with low HLA-I molecules expression
    via a partially HIF-dependent pathway. The low expression of HLA-I molecules by
    VHL-mutated RCC cells reduces the engagement of NKG2A inhibitory receptor, shifting
    the balance toward NK cell activation. Membrane HLA-G molecules upregulate inhibitory
    receptors (NKG2A,and ILT2) on NK cells. Membrane-bound IL15 (Mb-IL15) is involved
    in NK cell activation and survival. In CML, the oncogeneic protein bcr/abl induces
    the expression of ICAM-1 and NKG2D ligands on myeloid cells favoring NK/target
    conjugates and lysis. Altered IFNγ signaling in bcr/abl target maintains a low
    HLA-I molecules expression. Bcr/abl dendritic cells activate NK cells via NKG2D
    receptor. Imatinib mesylate interferes with NK/leukemic targets. DC: Dendritic
    cell; IM: Imatinib Mesylate; IRF: Interferon regulatory factor; STAT-1: Signal
    Transducer and Activator of Transcription factor-1.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - DCLK1
  - ADGRL1
  - CLU
  - AKR1C4
  - GZMB
  - POLR3K
  - HLA-G
  - KLRC1
  - LILRB1
  - HIF1A
  - EPAS1
  - HIF3A
  - ARNT
  - ARNT2
  - BMAL1
  - VHL
  - MMUT
  - XRCC1
  - PBRM1
  - IFNG
  - ICAM1
  - TRIM63
  - STAT1
  - BCR
  - RN7SL263P
  - ABL1
  - MTTP
  - DSP-AS1
  - ABL2
  - C15
  - Cli
  - eya
  - Vhl
  - Low
  - Irp-1B
  - Irp-1A
  - RhoGAP1A
  - Abl
  - Abi
---
